Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond(University of Western Australia), Lara Hatchuel(Linear Clinical Research), Min Dong(Clover Biopharmaceuticals (China)), Brenda Ma(Clover Biopharmaceuticals (China)), Branda Hu(Clover Biopharmaceuticals (China)), Igor Smolenov(Clover Biopharmaceuticals (China)), Ping Li(Clover Biopharmaceuticals (China)), Peng Liang(Clover Biopharmaceuticals (China)), Htay Htay Han(Clover Biopharmaceuticals (China)), Joshua G. Liang(Clover Biopharmaceuticals (China)), Ralf Clemens
The Lancet
January 29, 2021
Cited by 281Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis